Annals of Coloproctology

Original Article

Optimal Time Interval for Surgery After Neoadjuvant Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer: Analysis of Health Insurance Review and Assessment Service Data: Min Jung Kim, Jin Suk Cho, Eun Mi Kim, Woo Ah Ko, Jae Hwan Oh; Ann Coloproctol. 2018;34(5):241-247. Published online October 31, 2018; DOI: https://doi.org/10.3393/ac.2018.01.01

5,909 View
118 Download
18 Web of Science
19 Citations

Purpose
Pathologic downstaging of rectal cancer has been suggested to be associated with the time interval from chemoradiotherapy (CRT) completion to surgery. We aimed to evaluate the effect of this time interval for patients with rectal cancer on the pathologic response.
Methods
All patients with rectal cancer undergoing neoadjuvant CRT with evaluable data were selected from among the Health Insurance Review and Assessment Service data. Patients were divided into groups according to the time between CRT and surgery. CRT responses were analyzed.
Results
Two hundred forty-nine patients were included, of whom 86 (34.5%) were in the 5- to 7-week interval, 113 (45.4%) in the 7- to 9-week interval, 38 (15.3%) in the 9- to 11-week interval, and 12 (4.8%) in the >11-week interval. The median time interval between CRT completion and surgery was 7.4 weeks (range: 5–22.7 weeks; interquartile range, 6.7–8.7 weeks). Surgery 9–11 weeks after CRT completion resulted in the highest, but not statistically significant, pathologic complete response (pCR) rate (3 patients, 8.6%; P = 0.886), no pCR was noted in the >11-week interval group. Results for downstaging in the 9- to 11-week interval group were as follows: T downstaging, 38.2% (P = 0.735); N downstaging, 50.0% (P = 0.439); and TN downstaging, 52.9% (P = 0.087). The 3-year overall survival rates for the 5- to 7-week, 7- to 9-week, 9- to 11-week, and >11-week interval groups were 93.0%, 85.0%, 81.6%, and 91.7%, respectively (P = 0.326).
Conclusion
Delaying surgery by 9 to 11 weeks may increase TN downstaging, but delaying for over 11 weeks may not increase additional tumor downstaging from long-course CRT.

Citations

Citations to this article as recorded by

Time interval between neoadjuvant radiation therapy and surgery and overall survival of rectal cancer patients
Saber A Amin, Megha Patel, Chi Lin
Colorectal Cancer.2024;[Epub] CrossRef
Prediction of pathological complete response and prognosis in locally advanced rectal cancer
Yi-Jun Xu, Dan Tao, Song-Bing Qin, Xiao-Yan Xu, Kai-Wen Yang, Zhong-Xu Xing, Ju-Ying Zhou, Yang Jiao, Li-Li Wang
World Journal of Gastrointestinal Oncology.2024; 16(6): 2520. CrossRef
Determining the optimal radiation‐surgery interval (RSI) for oncologic proctectomy following radiotherapy for rectal adenocarcinoma
Matthew C. Bobel, Michael F. McGee
Journal of Surgical Oncology.2023; 127(8): 1252. CrossRef
A Predictive Model to Evaluate Pathologic Complete Response in Rectal Adenocarcinoma
Shuiwang Qing, Lei Gu, Tingting Du, Xiaolan Yin, Ke-jia Zhang, Huo-jun Zhang
Technology in Cancer Research & Treatment.2023;[Epub] CrossRef
Initial magnetic resonance imaging tumour regression grade (mrTRG) as response evaluation after neoadjuvant treatment predicts sustained complete response in patients with rectal cancer
Chikako Suzuki, Sandra Kapoun Halperin, Per J. Nilsson, Anna Martling, Torbjörn Holm
European Journal of Surgical Oncology.2022; 48(7): 1643. CrossRef
Does a long interval between neoadjuvant chemoradiotherapy and surgery benefit the clinical outcomes of locally advanced rectal cancer? A systematic review and meta analyses
Miao Yu, Deng-Chao Wang, Sheng Li, Li-Yan Huang, Jian Wei
International Journal of Colorectal Disease.2022; 37(4): 855. CrossRef
Machine Learning for Sensing Applications: A Tutorial
Vahideh Shirmohammadli, Behraad Bahreyni
IEEE Sensors Journal.2022; 22(11): 10183. CrossRef
Lymph Nodes With Germinal Centers Are Not Associated With Tumor Response After Neoadjuvant Treatment in Locally Advanced Rectal Cancer
Ihsane El Otmani, Boubacar Effared, Fatima El Agy, Mohammed El Abkari, Khalid Mazaz, El Bachir Benjelloun, Abdelmalek Ousadden, Zineb Benbrahim, Touria Bouhafa, Laila Chbani
Clinical Pathology.2022;[Epub] CrossRef
Predictors of pathological complete response following neoadjuvant chemoradiotherapy for rectal cancer
Asif Mehraj, Arshad A Baba, Bushra Khan, Mudassir Ahmad Khan, Rauf A Wani, Fazl Q Parray, Nisar A Chowdri
Journal of Cancer Research and Therapeutics.2022; 18(Suppl 2): S391. CrossRef
Timing to achieve the highest rate of pCR after preoperative radiochemotherapy in rectal cancer: a pooled analysis of 3085 patients from 7 randomized trials
Maria Antonietta Gambacorta, Carlotta Masciocchi, Giuditta Chiloiro, Elisa Meldolesi, Gabriella Macchia, Johan van Soest, Fenke Peters, Laurence Collette, Jean-Pierre Gérard, Samuel Ngan, C. Claus Rödel, Andrea Damiani, Andre Dekker, Vincenzo Valentini
Radiotherapy and Oncology.2021; 154: 154. CrossRef
Improvement in the Assessment of Response to Preoperative Chemoradiotherapy for Rectal Cancer Using Magnetic Resonance Imaging and a Multigene Biomarker
Eunhae Cho, Sung Woo Jung, In Ja Park, Jong Keon Jang, Seong Ho Park, Seung-Mo Hong, Jong Lyul Lee, Chan Wook Kim, Yong Sik Yoon, Seok-Byung Lim, Chang Sik Yu, Jin Cheon Kim
Cancers.2021; 13(14): 3480. CrossRef
Temporal determinants of tumour response to neoadjuvant rectal radiotherapy
Kendrick Koo, Rachel Ward, Ryan L. Smith, Jeremy Ruben, Peter W. G. Carne, Hany Elsaleh, Mona Pathak
PLOS ONE.2021; 16(6): e0254018. CrossRef
Factors Predicting Pathological Response to Neoadjuvant Chemoradiotherapy in Rectal Cancer: The Experience of a Single Institution with 269 Patients (STONE-01)
Michele Fiore, Pasquale Trecca, Luca E. Trodella, Roberto Coppola, Marco Caricato, Damiano Caputo, Alessandro Coppola, Gian M. Petrianni, Gabriele D’Ercole, Edy Ippolito, Rolando M. D’Angelillo, Sara Ramella
Cancers.2021; 13(23): 6074. CrossRef
Chemoradiotherapy alone or chemoradiotherapy followed by surgery in rectal cancer
Fabian Lunger, Georgios Peros
memo - Magazine of European Medical Oncology.2020; 13(3): 324. CrossRef
Preoperative Short-course Radiotherapy for Lower Rectal Cancer
Hidenori Yanagi, Naohito Beppu, Ryo Okamoto, Yoshihiko Nakamoto, Takayoshi Nakajima, Noriko Ichise, Tsukasa Aihara, Norihiko Kamikonya
Nippon Daicho Komonbyo Gakkai Zasshi.2020; 73(10): 424. CrossRef
Meta-analysis of the effect of extending the interval after long-course chemoradiotherapy before surgery in locally advanced rectal cancer
É J Ryan, D P O'Sullivan, M E Kelly, A Z Syed, P C Neary, P R O'Connell, D O Kavanagh, D C Winter, J M O'Riordan
British Journal of Surgery.2019; 106(10): 1298. CrossRef
Impact of PET/CT for Restaging Patients With Locally Advanced Rectal Cancer After Neoadjuvant Chemoradiation
Eric Sorenson, Fernando Lambreton, Jian Q. Yu, Tianyu Li, Crystal S. Denlinger, Joshua E. Meyer, Elin R. Sigurdson, Jeffrey M. Farma
Journal of Surgical Research.2019; 243: 242. CrossRef
Neoadjuvant radiotherapy for rectal cancer management
Gerard Feeney, Rishabh Sehgal, Margaret Sheehan, Aisling Hogan, Mark Regan, Myles Joyce, Michael Kerin
World Journal of Gastroenterology.2019; 25(33): 4850. CrossRef
Waiting and Hope: Optimal Time Interval for Surgery After Long-Course Neoadjuvant Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer
Chang Hyun Kim
Annals of Coloproctology.2018; 34(5): 227. CrossRef

First
Prev
Page of 1
Next
Last

Search